Cite

HARVARD Citation

    Felip, E. et al. (n.d.). LBA57Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3). Annals of oncology. p. . [Online]. 
  
Back to record